Medicines Co
Change company Symbol lookup
Select an option...
MDCO Medicines Co
ANPFF Anpulo Food Inc
FMCKJ Federal Home Loan Mortgage Corp
MMNFF Medmen Enterprises Inc
HD Home Depot Inc
DOC Physicians Realty Trust
FRGI Fiesta Restaurant Group Inc
QCOM Qualcomm Inc
ANTM Anthem Inc
SSREY Swiss Re AG
Go

Health Care : Pharmaceuticals | Small Cap BlendCompany profile

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin). It also has a pipeline of products in development, including Carbavance, inclisiran and MDCO-700. Carbavance is used for the treatment of hospitalized patients with gram-negative bacterial infections. Inclisiran is used for the treatment of hypercholesterolemia. MDCO-700 includes sedative-hypnotic, which is used to induce and maintain sedation for procedural care and general anesthesia for surgical care. In addition to these products and products in development, it has a portfolio of generic drugs.

Closing Price
$39.80
Day's Change
-0.28 (-0.70%)
Bid
--
Ask
--
B/A Size
--
Day's High
40.17
Day's Low
39.64
Volume
(Light)
Volume:
379,723

10-day average volume:
1,017,144
379,723

MDCO's position in the Pharmaceuticals industry

Industry PeersMDCOMRKLLYAMPHDEPO

Summary

Company ProfileThe Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital...
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through...
Go to MRK summary
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health...
Go to LLY summary
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and...
Go to AMPH summary
Depomed, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release...
Go to DEPO summary
52-Week Change

VS. INDUSTRY
1.84%
-0.67%
4.39%
-5.69%
-23.42%
Market Cap

VS. INDUSTRY
$3.0B
$168.2B
$97.1B
$775.7M
$519.5M
Beta

VS. INDUSTRY
0.7
0.8
0.2
1.3
1.2
Dividend Yield

VS. INDUSTRY
--
3.07%
2.54%
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
--
40.85x
30.65x
--
--
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$35.1M
$40.7B
$23.3B
$241.9M
$418.7M
Profit Margin

VS. INDUSTRY
-1,410.55%
10.32%
13.02%
-4.15%
-3.92%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
--
-1.94%
-14.98%
--
--
Revenue Growth (TTM)

VS. INDUSTRY
-68.19%
1.99%
8.14%
-4.19%
-5.18%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2018. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.